Skip to search formSkip to main contentSkip to account menu

Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme

Investigation of CAR T-cell therapy for B-ALL delivered on a country-wide basis, including following patients beyond therapy failure, provides clinicians with robust outcome measures and shows that patients can be successfully salvaged in this context with good short-term survival.
Springer Nature (opens in a new tab)

Practice guideline: Preparation for CAR T‐cell therapy in children and young adults with B‐acute lymphoblastic leukaemia

This guideline is to provide healthcare professionals with practical guidance on the preparation of children and young adults with B‐acute lymphoblastic leukaemia from the point of referral to that of admission for CAR T‐cell treatment.
Wiley (opens in a new tab)

A UK Intention to Treat Analysis of Brexucabtagene Autoleucel for Relapsed or Refractory Adult Acute Lymphoblastic Leukaemia Following 1 Year of Therapy Access

Evaluated use, toxicity and outcomes for patients approved within the first 12 months of Brexu-cel as the first EMA licensed, nationally approved CAR-T therapy for R/R adult B-ALL in the NHS.
Publisher (opens in a new tab)

The UK Impact Transplant Trials Network: An Effective National Strategy to Accelerate the Delivery of Randomized Trials in Stem Cell Transplantation

The success of the IMPACT pilot, which-out-performed its recruitment metrics by 300%, confirms the importance of innovative trial delivery models in accelerating recruitment to practice informing transplant studies and is a scalable model internationally.
Publisher (opens in a new tab)

Incorporation of 8Gy total body irradiation into reduced intensity conditioning does not improve allogeneic transplant outcomes for high-risk adult acute lymphoblastic leukemia: Results from the…

A prospective, randomised comparison of the UK FMA RIC regimen with a cyclophosphamide plus 8Gy TBI RIC protocol with the goal of improving OS in high-risk adult ALL, with the goal of improving OS in high-risk adult ALL.
Publisher (opens in a new tab)

An updated UK real-world analysis of factors affecting outcome following brexucabtagene autoleucel for relapsed or refractory adult acute lymphoblastic leukemia

An updated analysis of UK CAR-T use for adult ALL and factors influencing outcome following brexu-cel infusion finds MRD-negativity at infusion was associated with improved RFS and disease burden at infusion predicted outcome.
Publisher (opens in a new tab)

Bridging Pediatric B-Cell Acute Lymphoblastic Leukemia (ALL) Patients to CAR-T Cell Therapy: A National Perspective

Bridging therapy is given between leukapheresis and lymphodepletion to reduce disease burden or prevent progression and evidence to guide the choice of BT is scant, but evidence to guide the choice of BT is scant.
Publisher (opens in a new tab)

Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis

In 471 patients with B-ALL, by day 100 after tisa-cel, the infection density was 0.542 per 100 person-days at risk, and risk factors were ≥3 prior lines of therapy, any-grade cytokine release syndrome, and lack of neutrophil recovery.
PDF (opens in a new tab)

INO-transit: Inotuzumab ozogamicin treatment prior to chimeric antigen receptor T-cell therapy in Relapsed/Refractory B-cell acute lymphoblastic leukemia: Real-world patient characteristics and…

The INO-TRANSIT study aimed to describe the real-world demographics, clinical characteristics and treatment outcomes in R/R B-ALL patients treated with InO prior to CAR-T, and to assess the use and outcomes of InO prior to or as a bridging therapy to CAR-T.
Publisher (opens in a new tab)
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)